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The Renin-Angiotensin System (RAS)acts at multiple targets and has its synthesis machinery present in diﬀerent tissues, including
the heart. Actually, it is well known that besides Ang II, the RAS has other active peptides. Of particular interest is the heptapeptide
Ang-(1-7)thathasbeenshowntoexertcardioprotectiveeﬀects.Inthisway,greatcompilationsaboutAng-(1-7)actionsintheheart
have been presented in the literature. However, much less information is available concerning the Ang-(1-7) actions directly in
cardiomyocytes. In this paper, we show the actual knowledge about Ang-(1-7)-mediated signaling in cardiac cells more speciﬁcally
weprovideabriefoverviewofACE2/Ang-(1-7)/Masaxis;andhighlightthediscoveriesmadeincardiomyocytephysiologythrough
the use of genetic approaches. Finally, we discuss the protective signaling induced by Ang-(1-7) in cardiomyocytes and point
molecular determinants of these eﬀects.
1.Introduction
Arterialhypertensionisanimportantcardiovascularriskfac-
tor and contributes to the development of cardiovascular
event. Despite the substantial advances in antihypertensive
drug therapy, the number of patients with uncontrolled hy-
pertension remains high around the world [1].
The renin-angiotensin system (RAS) is an important
classical player that directly contributes to the development
andmaintenanceofessentialhypertension[2].Thissystemis
classically known as a hormonal system, involved in salt and
water regulation and blood pressure control. Angiotensin
(Ang) II, one of the main components of the RAS, exerts its
biological eﬀects by binding with high aﬃnity to two distinct
subtypes of receptor, the angiotensin II type 1 receptor
(AT1R) and the angiotensin II type 2 receptor (AT2R) [3, 4].
Under physiological and pathological states, it is recognized
that AT1R plays a critical role in Ang II-mediated actions in
the cardiovascular system [3, 4]. On the other hand, a large
body of evidence suggests that AT2R antagonizes the eﬀects
of AT1R preventing, between other eﬀects, its hypertrophic
and angiogenic eﬀects [5, 6].
Although Ang II is the major eﬀector of this system,
several other peptides are now recognized as being biologi-
cally important. Of particular importance is the heptapep-
tide Ang-(1-7) that decades ago emerged as a new metabolite
of the RAS. Ang-(1-7) was initially detected as an Ang I met-
abolite in canine brain homogenates [7]. This discovery led
to the later demonstration of its action in releasing vaso-
pressin from hypophyseal-hypothalamic explants [8]a n d
in counteracting the pressor and baroreﬂex eﬀects of Ang
II [9–11]. Later on, Ang-(1-7) was ﬁnally recognized as a
putative biologically active component of the RAS [12–14].
Since then, the physiological actions of Ang-(1-7) have been
extensively investigated. The heart is an important target for
Ang-(1-7), which exerts direct eﬀects on cardiomyocytes.
The following sections focus on the cellular mechanism
and signaling pathways involved in Ang-(1-7) actions in the
cardiac cell, with particular emphasis on recent discoveries
made through the use of genetic approaches.2 International Journal of Hypertension
2. The Angiotensin-Converting
Enzyme2/Angiotensin-(1-7)/MasAxis
Ang-(1-7) can be formed directly from Ang I or Ang II and
indirectly from Ang I having as an intermediate step the
formation of Ang-(1-9) [14, 15]. Angiotensin-converting
enzyme (ACE) 2, as well as prolylcarboxypeptidase (PCP)
and prolylendopeptidase (PEP), can generate Ang-(1-7)
directly from Ang II. Apparently, the principal enzyme
and pathway involved in the Ang-(1-7) generation is ACE2
throughthehydrolysisofAngII[16,17].However,Campbell
et al. [18] have suggested that PEP is the main enzyme
responsible for generating Ang-(1-7) from Ang II in human
coronary vessels. In addition, it appears that the generation
of Ang-(1-7) involving an intermediate step, including the
hydrolysis of Ang I to Ang-(1-9), is less important [19]. Ang-
(1-7) is also produced directly from Ang I by neutral en-
dopeptidase (NEP) and PEP through hydrolysis of the Pro7-
Phe8 bond [19, 20]. A schematic representation of the
enzymatic pathways involved in the generation of Ang-(1-7)
is presented in Figure 1.
In cardiomyocytes the expression of ACE2, the main
enzyme involved in Ang-(1-7) formation, was already
demonstrated [21, 22], as well as NEP [23]. In addition,
ACE mRNA has been consistently demonstrated in cardiac
cells [24, 25] .H o w e v e r ,t h eA C Em R N Al e v e l sw e r en o t
supported by protein measurements in human hearts.
No immunoreactivity for ACE was found in ventricular
myocytes from human control hearts, with ACE detected
only in cardiomyocytes from hearts after myocardial infarc-
tion [26]. Nevertheless, ACE has been demonstrated in car-
diomyocytes from rats and mice by enzyme-kinetic and
immunohistochemical methods [27]. The presence in the
cardiomyocyte of these speciﬁc enzymes indicates that Ang-
(1-7) and some of RAS components can be locally syn-
thesized in the heart. It remains to be determined which
components are produced locally and in which conditions
t h i sp r o d u c t i o ni sa c t i v a t e d .
The identiﬁcation of ACE2 as an important Ang-(1-7)-
forming enzyme [28, 29], and of Mas as a G protein-coupled
receptor for Ang-(1-7) [30], contributed to establish Ang-(1-
7) as a biologically active component of the RAS. In 2005,
FerreiraandSantosadvancedthehypothesisthatACE2,Ang-
( 1 - 7 ) ,a n dM a sc o u l db ec o n s i d e r e da sc o m p o n e n t so fa
novel axis of the RAS, the so-called ACE2/Ang-(1-7)/Mas
axis [31]. For the heart, this concept is now quite well
accepted in the literature [13, 32–35]. But, at present, only
limited information is available regarding the direct eﬀects
of ACE2/Ang-(1-7)/Mas axis activation for cardiomyocyte
function during physiological as well as in pathological
conditions. In addition to ACE2, the presence of Mas has
been demonstrated in cardiomyocytes from diﬀerent species
[21, 22, 36, 37], including humans [38].
A variety of vasoactive peptides and hormones can reg-
ulate ACE2 mRNA levels in cardiomyocytes. Modulation of
ACE2 mRNA levels by aldosterone has been demonstrated
in neonatal cardiomyocytes treated with this mineralocorti-
coid [22]. Accordingly, aldosterone decreased ACE2 mRNA
levels in these cells, an eﬀect apparently mediated by the
mineralocorticoid receptor. In the same study, ACE2 mRNA
modulation was not aﬀected by Ang II treatment, suggesting
that ACE2 mRNA expression is under diﬀerential modula-
tion by endocrine molecules in cardiomyocytes. Considering
the Ang II actions on ACE2 mRNA levels, opposing results
were obtained by Gallagher et al. [21], who found a decrease
in ACE2 activity and downregulation of its mRNA by Ang II.
Importantly, this eﬀect was mediated by AT1Ra n db l o c k e d
by inhibitors of mitogen-activated protein kinase kinase 1
(MAPKK1). Considering that diﬀerences in experimental
conditions can explain the contrasting results regarding Ang
II modulation of ACE2, further investigation will be neces-
sary to elucidate the speciﬁc mechanism involved in ACE2
downregulationincardiomyocytes.Endothelin-1(ET-1)also
signiﬁcantly reduced myocyte ACE2 mRNA via MAPKK1
activation [21]. Apparently Ang-(1-7) has no direct eﬀect on
ACE2 mRNA regulation, although this peptide, through Mas
receptor, blocked the Ang II and ET-1 mediated downreg-
ulation of ACE2 expression [21]. Collectively, these results
indicate that ACE2 expression in cardiomyocytes is tightly
regulatedbyimportantmodulatorsofcardiovascularsystem,
highlighting its importance in cardiac disease establishment
and progression. Since ACE2 converts Ang II to Ang-(1-7),
it is plausible that ACE2 downregulation by Ang II serves
as a mechanism to favor Ang II-mediated responses, by
preventing its degradation to Ang-(1-7). Thus, conditions
favoring excess Ang II generation and reduced Ang II
breakdown would likely lead to more deleterious eﬀects on
the heart. Figure 2 summarizes the information regarding
the modulation of ACE2 expression in cardiomyocytes.
3.ProtectiveSignalingInducedby
ACE2/Ang-(1-7)/MasAxisin
Cardiomyocytes
In the past two decades, since the detection of the Ang-(1-7)
as a product of the metabolism of Ang I, the physiological
actions of Ang-(1-7) have been extensively investigated, and
Ang-(1-7) was ﬁnally recognized as a putative biologically
active component of the RAS [12–14]. However, besides this
great advance in the understanding of Ang-(1-7) actions,
especially in the heart, only a few reports have explored the
Ang-(1-7) actions directly in cardiomyocytes. This section
willfocusonsignalingpathwaysandmoleculardeterminants
of Ang-(1-7) signaling in cardiomyocytes. This will be
accomplished by highlighting the following eﬀects: (1) anti-
hypertrophic, (2) anti-inﬂammatory, and (3) antioxidative.
In addition, we summarize current knowledge regarding
Ang-(1-7) modulation of Ca2+ handling in cardiomyocytes.
Initial studies were performed by Tallant et al. [39], who
conﬁrmed the presence of the Mas receptor in neonatal car-
diomyocytes and showed a direct eﬀect of Ang-(1-7) in
these cells, by preventing cell growth, through inhibition of
the MAPK ERK1/2 activity. Later on, it was demonstrated
the presence of Mas receptor in adult ventricular myocytes
[40]. Continuing the exploration of Ang-(1-7) actions and
pathwaysincardiomyocytes,someinformationcomingfromInternational Journal of Hypertension 3
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Figure 1: Schematic representation of the enzymatic pathways involved in the generation of Ang-(1-7). Ang-(1-7) can be formed by at least
three diﬀerent pathways: directly from Ang I by NEP and PEP, by hydrolysis of Ang II by ACE2, PEP, and PCP, and ﬁnally by hydrolysis of
Ang-(1-9) by ACE and NEP. ACE, ACE2, and NEP are found in cardiomyocytes.
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Figure 2: Schematic illustration of ACE2 modulation in cardiomyocytes by diﬀerent molecules. Ang II, and ET-1 through MAPKK1
activation, and aldosterone lead to ACE2 mRNA downregulation. To date no reported eﬀects of Ang-(1-7) on ACE2 levels have been
demonstrated, although this peptide is capable of antagonizing Ang II and ET-1 eﬀects on ACE2 mRNA. Conditions that favor ACE2
downregulation would likely lead to more deleterious eﬀects during cardiovascular disease development.→= activation; - - = inhibition;
ET-1 = endothelin; Ang II = angiotensin II; Ang-(1-7) = angiotensin-(1-7); ET-R = endothelin receptor; AT1-R = AT1 receptor; Mas = Mas
receptor; MR = mineralocorticoid receptor; MAPKK1 = mitogen-activated protein kinase kinase 1.
diﬀerent types of cell supported the next steps in the under-
standing of the signaling molecules involved in the Ang-(1-
7) eﬀects. Sampaio et al. [41] showed that in endothelial
cells Ang-(1-7) was able to generate nitric oxide (NO). In
the same way, Dias-Peixoto et al. [36] demonstrated that
Ang-(1-7) was able to activate the phosphatidylinositol 3-
kinase (PI3-K)-protein kinase B (Akt)-pathway, resulting in
nitric oxide synthase (NOS) 3 activation and NO generation
in adult ventricular cardiomyocytes. It should be noted that
cardiomyocytes express distinct subtypes of PI3-K, and some
of them are activated by Ang II [42, 43]. Therefore, is of
particular importance to investigate which speciﬁc pools of
PI3-K are regulated by Ang II and Ang-(1-7). In addition,
Dias-Peixoto et al. [36] have shown that expression levels4 International Journal of Hypertension
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Figure 3: Ang-(1-7) signaling in cardiomyocytes. Ang-(1-7) activates the PI3-K/AKT/NOS3 pathway leading to NO generation and cGMP
production. Activation of this pathway culminates with inhibition of Ang II-induced NFAT translocation. Preliminary evidence suggests
that NOS1 expression may be modulated by Ang-(1-7). Ang-(1-7) also inhibits ET-1 and FBS activation of cell growth. The consequences of
Ang-(1-7)/Mas and B2R cross-talk for cardiomyocyte function are still unknown (?). →= activation; - - = inhibition; ET-1 = endothelin;
Ang II = angiotensin II; Ang-(1-7) = angiotensin-(1-7); ET-R = endothelin receptor; AT1-R = AT1 receptor; Mas = Mas receptor; B2R=
bradykinin receptor type 2; FBS = fetal bovine serum; NFAT = nuclear factor of activated T cells; GSK3β = glycogen synthase kinase 3β;
PI3-K = phosphatidylinositol 3-kinase; AKT = protein kinase B; NOS3 = nitric oxide synthase 3; NOS1 = nitric oxide synthase 1; NO = nitric
oxide; cGMP = cyclic guanosine monophosphate; ERK 1/2 = extracellular signal regulated kinase 1/2. The question marks denote areas in
which the current state of knowledge is still preliminary.
of proteins involved in the NOS3 macromolecular complex,
such as caveolin-3, heat shock protein (HSP)-90, and protein
kinase B (AKT), were altered in ventricular myocytes from
Mas−/− (Mas knockout) mice, indicating an important re-
lationship between NOS3 activity and Ang-(1-7)/Mas axis.
Initial investigation into the cellular mechanisms underlying
protective eﬀects of Ang-(1-7) against Ang II signaling was
recently performed by our laboratory. Gomes et al. [37]h a v e
demonstrated, in cardiomyocytes, that Ang-(1-7) prevention
of Ang II-induced pathological remodeling is mediated by
NO/cGMP(cyclicguanosinemonophosphate)pathway.This
result identiﬁes a role of NO as mediator of Ang-(1-7)
beneﬁcial eﬀects and extends the concept that cGMP is
another key molecule in this signaling pathway. In addition,
this study showed that transgenic rats presenting increased
Ang-(1-7) plasmatic levels have higher levels of NOS1 in
ventricular cardiomyocytes, showing that besides NOS3,
NOS1 shall be involved in NO generation elicited by Ang-(1-
7).Ang-(1-7)alsomodulatedtheactivityofthetranscription
factor NFAT (nuclear factor of activated T cells), preventing
its translocation to the nucleus, and the activation of
hypertrophic gene program by Ang II [37]. Stimulated by
calcium signals, NFAT is translocated to the nucleus where
it can regulate hypertrophic genes. In cardiomyocytes, NFAT
nuclear localization is tightly controlled at multiple levels
[44–46].Glycogensynthasekinase3β (GSK3β),inparticular,
is considered a potent inhibitor of this pathway downstream
of calcineurin. In the nucleus, GSK3β phosphorylates NFAT,
thereby promoting its nuclear export [44]. Moreover, GSK3β
has been shown to regulate hypertrophy development by
restraining gene expression [47]. Gomes et al. [37]h a v e
shown that Ang-(1-7) modulates the activity of GSK3-β,
by preventing its inactivation by Ang II. The modulation
of these two proteins, NFAT and GSK3- β, supports the
anti-hypertrophic eﬀect of Ang-(1-7) observed in the heart
[37] and in cardiomyocytes [37, 39]. Corroborating these
ﬁndings Flores-Mu˜ noz et al. [48] reported that Ang-(1-7)
was able to block the increase in cell size induced by Ang
II in H9c2 cardiomyocytes. These eﬀects were mediated by
Mas receptor, since Mas antagonist A779 eﬃciently blocked
the antihypertrophic eﬀects of Ang-(1-7). Importantly, these
authors have also shown that Ang-(1-7) anti-hypertrophic
activity was inhibited in the presence of the bradykinin type
2r e c e p t o r( B 2R) antagonist, HOE140, suggesting a cross-
talk between Mas and B2R in response to Ang-(1-7). Figure 3
shows recent data about Ang-(1-7) signaling and cross-talk
in cardiomyocytes.
Recently, Qi et al. have provided evidence for an anti-
inﬂammatory role of angiotensin-(1-7) at the cardiomyocyte
level [49]. By using neonatal cardiomyocyte culture, the
authors demonstrated that protective eﬀects of Ang-(1-7)
against hypoxia-induced cell death were mediated, at least
in part, through modulation of cytokine production. This
beneﬁcial eﬀect was associated with decreased expressionInternational Journal of Hypertension 5
of inﬂammatory cytokines such as tumor necrosis factor-α
(TNF-α) and interleukin-6 (IL-6) and increased gene expres-
sion of ACE2, bradykinin type 2 receptor, and interleukin-
10 (IL-10). Taken together, these data show that Ang-(1-7)
regulates cytokine responses, which could contribute to its
cardioprotective eﬀects.
Considering the critical role of Ca2+ ions for cardiomy-
ocyte contraction [50], some studies have addressed whether
Ang-(1-7)modulatesCa2+ handlinginventricularcardiomy-
ocytes. Recent work by our group has shown that acute Ang-
(1-7) treatment does not signiﬁcantly alter Ca2+ transient
amplitude or kinetics of decay [36]. We extended these ﬁnd-
ings to in vivo conditions and showed that cardiomyocytes
from transgenic (TG) rats with chronic elevated plasmatic
Ang-(1-7) do not show alteration in cytosolic Ca2+ transient
parameters [37]. Interestingly, cardiomyocytes from mice
with genetic ablation of Ang-(1-7) Mas receptor (Mas−/−)
presented a Ca2+ signaling dysfunction represented by a
smaller peak Ca2+ transient and slower Ca2+ uptake. This
Ca2+ signaling dysfunction was accompanied by decreased
protein levels of the sarcoplasmic/endoplasmic reticulum
Ca2+ ATPase 2 (SERCA2) [36]. SERCA2 is responsible for
Ca2+ reuptake by the sarcoplasmic reticulum (SR), thereby
setting SR Ca2+ load, which is an important determinant of
Ca2+ release in cardiomyocytes [50]. The reduction in the
Ca2+ transient is consistent with the depression of contractil-
ity that was previously observed in Mas −/− hearts [40]. This
ﬁnding was particularly important since it suggested that the
Ang-(1-7)/Mas axis is critical for long-term maintenance of
normal Ca2+ handling in the cardiac cell. However, there
was still the possibility that the alterations in Ca2+ handling
found in Mas−/− cardiomyocytes were secondary to the
cardiac dysfunction observed in these hearts.
Adding further complexity to the understanding of Ang-
(1-7)/Mas modulation of cardiomyocyte Ca2+ signaling, it
was also shown that cardiomyocytes from TG rats with car-
diac speciﬁc overexpression of Ang-(1-7) presented higher
Ca2+ transient amplitude, faster Ca2+ uptake, and increased
levels of SERCA2 [51], suggesting that chronic local increase
of Ang-(1-7) in the heart was associated to enhanced Ca2+
handling. Are these changes in Ca2+ handling a direct
consequence of local Ang-(1-7) increase in the heart? These
ﬁndings contrasted with the lack of eﬀect on Ca2+ signaling
found in cardiomyocytes from TG rats with chronic elevated
plasmatic Ang-(1-7) levels. As it stands, the relationship
between Ang-(1-7) and Ca2+ signaling is more complex
than one may have anticipated. It is also plausible, that
Ang-(1-7) eﬀects on Ca2+ handling observed in an in vivo
model of chronic Ang-(1-7) overexpression in the heart
are consequences of long-term changes in expression levels
of Ca2+ handling proteins. Future studies are needed to
demonstrate whether Ang-(1-7) prevents Ca2+ signaling
dysfunction in ventricular myocytes from animal models of
heart failure.
NO has been attributed as a key mediator of Ang-(1-7)
eﬀects on diﬀerent cell types, including cardiomyocytes, and
it is known to interact with proteins involved in Ca2+ han-
dlingandregulatecardiaccontractility.Thequestionremains
whether long-term Ang-(1-7) eﬀects on Ca2+ handling are
mediated by NO or other signaling molecules in cardiomy-
ocytes. In this way, the regulation of some key proteins
involved in cardiomyocyte Ca2+ handling, such as ryanodine
receptor(RyR),phospholamban(PLN),Na+/Ca2+ exchanger
(NCX), and troponins by Ang-(1-7) must be investigated
in order to provide a deeper understanding of Ang-(1-7)
actions on Ca2+ signaling. A summary of current knowledge
regardingAng-(1-7)/MasmodulationofcardiomyocyteCa2+
signaling is shown in Figure 4.
Evidence for a direct role of ACE2/Ang-(1-7)/Mas
axis against oxidative stress in cardiomyocytes was also
obtained [52]. Experiments on adult ventricular myocytes
demonstrated that Ang II-mediated superoxide generation
and extracellular signal-regulated kinase 1/2 (ERK 1/2)
activation were inhibited by recombinant ACE2 (rhACE2).
Importantly, these eﬀects were mediated by Ang-(1-7), since
preincubation with the Mas receptor peptide antagonist,
D-Ala7-Ang-(1-7), largely prevented rhACE2 suppression
of Ang II-induced responses in cardiomyocytes. These in
vitro ﬁndings correlated with in vivo data showing that
treatment with rhACE2 prevented Ang II–induced hyper-
trophy and myocardial ﬁbrosis. Thus, these ﬁndings give
furthersupporttothefactthatenhancedAng-(1-7)signaling
at the cardiomyocyte level prevents Ang II pathological
eﬀects and highlight Ang-(1-7) anti-oxidative actions on
cardiomyocytes.
ContrastingtotheviewofaprotectiveroleofACE2/Ang-
(1-7)/Mas axis some reports have shown hypertrophic
eﬀects of ACE2 and Mas overexpression in cardiomyocytes.
Masson et al. [53] reported that adenoviral-mediated gene
transfer of ACE2 in rabbit cardiomyocytes leads to cellular
hypertrophy. In the same study, in vivo ACE2 overexpres-
sion in the myocardium of stroke-prone spontaneously
hypertensive rats resulted in profound cardiac dysfunction.
The authors have argued that the detrimental eﬀects of
ACE2 overexpression were possibly due to higher amounts
of protein expressed using this approach. Using similar
overexpression strategy, neonatal rat cardiomyocytes were
infected with adenovirus encoding the human Mas receptor.
Intriguingly, overexpression of Mas induced a signiﬁcant
increaseinIP3accumulationandcellularhypertrophy.These
responses were due to enhanced Gq-mediated signaling via
Mas receptor [38]. Whether this response is a consequence
of exacerbated Mas signaling or is a result of promiscu-
ous signaling activation caused, for example, by hetero-
dimerization, it is a topic that needs further clariﬁcation.
Therefore, understanding the role of “physiological” versus
“supraphysiological”levelsofACE2andMas,itsdownstream
signaling pathways and their functional outcomes are crucial
for clarifying the role of ACE2/Ang-(1-7)/Mas axis for
cardiomyocyte function.
4. Conclusions and Perspectives
In cardiomyocytes, the actual knowledge of Ang-(1-7)
protective eﬀects was mainly focused on the modulation of
AngIIsignalingwithemphasisonanti-hypertrophicactions.
This eﬀect was dependent on Mas, indicating that important6 International Journal of Hypertension
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Figure 4: Summary of current knowledge regarding Ang-(1-7) modulation of Ca2+ handling in ventricular myocytes and the underlying
mechanisms. Acute treatment of cardiomyocytes with Ang-(1-7) apparently has no direct eﬀect on Ca2+ handling (black circle, left).
Lack of eﬀect on Ca2+ levels was also observed in cardiomyocytes from TG rats with increased circulating levels of Ang-(1-7) (black
circle, middle). In contrast, Ang-(1-7) signaling disruption through Mas genetic ablation (Mas KO) leads to Ca2+ dysfunction (red circle,
right). Cardiomyocytes from Mas KO mice present reduced SERCA expression levels and Ca2+ transients (red arrows). Cardiac speciﬁc
overexpression of Ang-(1-7) enhances Ca2+ release and SERCA levels in ventricular myocytes (green circle and arrows). Data regarding
Ang-(1-7) modulation of some other key proteins involved in Ca2+ handling in ventricular myocytes, such as PLN, NCX, TnI, and TnC,
are still missing. Black ﬁlled circles= calcium ions; LTCC= L-type Ca2+channels; Mas= Mas receptor; NCX= Na+/Ca2+ exchanger; PLB=
phospholamban; RyR= ryanodine receptor; TnC= troponin C; TnI= troponin I.
cardioprotective aspects of Ang-(1-7) signaling are mediated
through Mas receptor, and involved NO and cGMP genera-
tion. It remains to be elucidated whether antioxidative and
anti-inﬂammatory responses of Ang-(1-7) also depend on
NO/cGMP production. A direct acute eﬀect of Ang-(1-7) on
Ca2+ signaling in cardiomyocytes seems unlikely. However,
there still are many ways by which Ang-(1-7) may regulate
Ca2+ signaling in ventricular myocytes. Chronic increase in
local Ang-(1-7) levels could be a mechanism by which Ang-
(1-7)enhancesCa2+ handling,asobservedincardiomyocytes
from transgenic rats with cardiac speciﬁc overexpression
of Ang-(1-7). To understand how Ang-(1-7) regulates Ca2+
handling in ventricular myocytes is of fundamental impor-
tance in light of Ang-(1-7) therapeutic potential in several
disease conditions. The literature shows a tight control of
ACE2 synthesis and activity in cardiomyocytes. How this
enzyme expression is modulated, the signaling pathways
involved in this regulation, and whether this occurs in vivo
are questions that remain to be answered, considering the
pivotal role of ACE2 as modulator of Ang II/Ang-(1-7)
levels. The actions of Ang-(1-7) on cardiomyocytes are just
beginning to unravel, dissecting the signaling pathways, and
the conditions under which Ang-(1-7) signaling is turned on
will be a major issue to be addressed in the future.
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